Corrigendum: Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzheimer's disease model(Nature Communications (2014) 5:4159 DOI: 10.1038/ncomms5159);Tonic inhibition in dentate gyrus impairs long-term potentiation and memory in an Alzhiemer' s disease model

Nature Communications

Volumn 5, Issue , 2014, Pages

  Wu, Zheng ^a   Guo, Ziyuan ^a   Gearing, Marla ^b   Chen, Gong ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; GABA TRANSPORTER 1; GABA TRANSPORTER 3; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 67; GLUTAMIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR;

DISEASE PREVALENCE; INHIBITION; NUMERICAL MODEL; ORGANIC ACID;

4 AMINOBUTYRIC ACID RELEASE; ALZHEIMER DISEASE; AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BRAIN ELECTROPHYSIOLOGY; BRAIN HOMOGENATE; CELL LEVEL; COGNITION; CONTROLLED STUDY; DENTATE GYRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GRANULE CELL; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LONG TERM POTENTIATION; MALE; MEMORY; MOTOR ACTIVITY; MOUSE; NERVE CELL MEMBRANE CONDUCTANCE; NERVE CELL MEMBRANE STEADY POTENTIAL; NERVE ENDING; NONHUMAN; PATCH CLAMP TECHNIQUE; PYRAMIDAL NERVE CELL; TONIC INHIBITION; UPREGULATION; Y-MAZE TEST; ANIMAL; C57BL MOUSE; CYTOLOGY; DISEASE MODEL; GENETICS; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; ASTROCYTES; DENTATE GYRUS; DISEASE MODELS, ANIMAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LONG-TERM POTENTIATION; MALE; MEMORY; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, GABA-A;

EID: 84902438828     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms5810     Document Type: Erratum

References (60)

1. Tomiyama, T. et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann. Neurol. 63, 377-387 (2008). (Pubitemid 351499867)
2. Benilova, I., Karran, E. & De Strooper, B. The toxic Abeta oligomer and Alzheimer's disease: an emperor in need of clothes. Nat. Neurosci. 15, 349-357 (2012).
3. Walsh, D. M. et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535-539 (2002). (Pubitemid 34288854)
4. Roberson, E. D. & Mucke, L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 314, 781-784 (2006). (Pubitemid 44706637)
5. Roberson, E. D. et al. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316, 750-754 (2007). (Pubitemid 46717684)
6. Shankar, G. M. et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med. 14, 837-842 (2008).
7. Klyubin, I. et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat. Med. 11, 556-561 (2005). (Pubitemid 40685979)
8. Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P. & Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet. Neurol. 9, 702-716 (2010).
9. Imbimbo, B. P. & Giardina, G. A. Gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr. Top. Med. Chem. 11, 1555-1570 (2011).
10. Schor, N. F. What the halted phase III gamma-secretase inhibitor trial may (or may not) be telling us. Ann. Neurol. 69, 237-239 (2011).
11. Wu, X. et al. Gamma-aminobutyric acid type A (GABAA) receptor alpha subunits play a direct role in synaptic versus extrasynaptic targeting. J. Biol. Chem. 287, 27417-27430 (2012).
12. Wu, X. et al. Homeostatic competition between phasic and tonic inhibition. J. Biol. Chem. 288, 25053-25065 (2013).
13. Brickley, S. G. & Mody, I. Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease. Neuron 73, 23-34 (2012).
14. Glykys, J., Mann, E. O. & Mody, I. Which GABA(A) receptor subunits are necessary for tonic inhibition in the hippocampus? J. Neurosci. 28, 1421-1426 (2008). (Pubitemid 351231514)
15. Schwab, C., Yu, S., Wong, W., McGeer, E. G. & McGeer, P. L. GAD65, GAD67, and GABAT immunostaining in human brain and apparent GAD65 loss in Alzheimer's disease. J. Alzheimers Dis. 33, 1073-1088 (2013).
16. Verret, L. et al. Inhibitory interneuron deficit links altered network activity and cognitive dysfunction in Alzheimer model. Cell 149, 708-721 (2012).
17. Oakley, H. et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci. 26, 10129-10140 (2006). (Pubitemid 44527407)
18. Sofroniew, M. V. & Vinters, H. V. Astrocytes: biology and pathology. Acta Neuropathol. 119, 7-35 (2010).
19. Palop, J. J. et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55, 697-711 (2007). (Pubitemid 47321079)
20. Steele, M. L. & Robinson, S. R. Reactive astrocytes give neurons less support: implications for Alzheimer's disease. Neurobiol. Aging 33, e1-13 (2010).
21. Verkhratsky, A., Olabarria, M., Noristani, H. N., Yeh, C. Y. & Rodriguez, J. J. Astrocytes in Alzheimer's disease. Neurotherapeutics 7, 399-412 (2010).
22. Madsen, K. K., White, H. S. & Schousboe, A. Neuronal and non-neuronal GABA transporters as targets for antiepileptic drugs. Pharmacol. Ther. 125, 394-401 (2010).
23. Heja, L. et al. Glutamate uptake triggers transporter-mediated GABA release from astrocytes. PLoS ONE 4, e7153 (2009).
24. Mehta, A., Prabhakar, M., Kumar, P., Deshmukh, R. & Sharma, P. L. Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur. J. Pharmacol. 698, 6-18 (2013).
25. Sperk, G., Schwarzer, C., Tsunashima, K., Fuchs, K. & Sieghart, W. GABA(A) receptor subunits in the rat hippocampus I: immunocytochemical distribution of 13 subunits. Neuroscience 80, 987-1000 (1997). (Pubitemid 27359787)
26. Brown, N., Kerby, J., Bonnert, T. P., Whiting, P. J. & Wafford, K. A. Pharmacological characterization of a novel cell line expressing human alpha(4)beta(3)delta GABA(A) receptors. Br. J. Pharmacol. 136, 965-974 (2002).
27. Hutcheon, B., Fritschy, J. M. & Poulter, M. O. Organization of GABA receptor alpha-subunit clustering in the developing rat neocortex and hippocampus. Eur. J. Neurosci. 19, 2475-2487 (2004). (Pubitemid 38621845)
28. Semyanov, A., Walker, M. C. & Kullmann, D. M. GABA uptake regulates cortical excitability via cell type-specific tonic inhibition. Nat. Neurosci. 6, 484-490 (2003). (Pubitemid 36514696)
29. Kaplan, J. S., Mohr, C. & Rossi, D. J. Opposite actions of alcohol on tonic GABAA receptor currents mediated by nNOS and PKC activity. Nat. Neurosci. 16, 1783-1793 (2013).
30. Clarke, L. E. & Barres, B. A. Emerging roles of astrocytes in neural circuit development. Nat. Rev. Neurosci. 14, 311-321 (2013).
31. Stobart, J. L. & Anderson, C. M. Multifunctional role of astrocytes as gatekeepers of neuronal energy supply. Front. Cell. neurosci. 7, 38 (2013).
32. Molofsky, A. V. et al. Astrocytes and disease: a neurodevelopmental perspective. Genes Dev. 26, 891-907 (2012).
33. Halassa, M. M., Fellin, T. & Haydon, P. G. The tripartite synapse: roles for gliotransmission in health and disease. Trends. Mol. Med. 13, 54-63 (2007). (Pubitemid 46186152)
34. Danbolt, N. C. Glutamate uptake. Prog. Neurobiol. 65, 1-105 (2001). (Pubitemid 32479155)
35. Ochi, S. et al. Transient presence of GABA in astrocytes of the developing optic nerve. Glia 9, 188-198 (1993).
36. Lee, S. et al. Channel-mediated tonic GABA release from glia. Science 330, 790-796 (2010).
37. Lee, M., McGeer, E. G. & McGeer, P. L. Mechanisms of GABA release from human astrocytes. Glia 59, 1600-1611 (2011).
38. Lee, M., Schwab, C. & McGeer, P. L. Astrocytes are GABAergic cells that modulate microglial activity. Glia 59, 152-165 (2011).
39. Angulo, M. C., Le Meur, K., Kozlov, A. S., Charpak, S. & Audinat, E. GABA, a forgotten gliotransmitter. Prog. Neurobiol. 86, 297-303 (2008).
40. Lin, R. C., Polsky, K. & Matesic, D. F. Expression of gamma-aminobutyric acid immunoreactivity in reactive astrocytes after ischemia-induced injury in the adult forebrain. Brain Res. 600, 1-8 (1993). (Pubitemid 23034245)
41. Conti, F., Minelli, A. & Melone, M. GABA transporters in the mammalian cerebral cortex: localization, development and pathological implications. Brain. Res. Rev. 45, 196-212 (2004). (Pubitemid 38802871)
42. Mitew, S., Kirkcaldie, M. T., Dickson, T. C. & Vickers, J. C. Altered synapses and gliotransmission in Alzheimer's disease and AD model mice. Neurobiol. Aging 34, 2341-2351 (2013).
43. Richerson, G. B. & Wu, Y. Dynamic equilibrium of neurotransmitter transporters: not just for reuptake anymore. J. Neurophysiol. 90, 1363-1374 (2003). (Pubitemid 37129348)
44. Kersante, F. et al. A functional role for both-aminobutyric acid (GABA) transporter-1 and GABA transporter-3 in the modulation of extracellular GABA and GABAergic tonic conductances in the rat hippocampus. J. Physiol. 591, 2429-2441 (2013).
45. Laurie, D. J., Wisden, W. & Seeburg, P. H. The distribution of thirteen GABAA receptor subunit mRNAs in the rat brain. III. Embryonic and postnatal development. J. Neurosci. 12, 4151-4172 (1992).
46. Collinson, N. et al. Enhanced learning and memory and altered GABAergic synaptic transmission in mice lacking the alpha 5 subunit of the GABAA receptor. J. Neurosci. 22, 5572-5580 (2002). (Pubitemid 35386478)
47. Crestani, F. et al. Trace fear conditioning involves hippocampal alpha5 GABA(A) receptors. Proc. Natl Acad. Sci. USA 99, 8980-8985 (2002). (Pubitemid 34693669)
48. Braudeau, J. et al. Specific targeting of the GABA-A receptor alpha5 subtype by a selective inverse agonist restores cognitive deficits in Down syndrome mice. J. Psychopharmacol. 25, 1030-1042 (2011).
49. Wigstrom, H. & Gustafsson, B. Facilitated induction of hippocampal long-lasting potentiation during blockade of inhibition. Nature 301, 603-604 (1983). (Pubitemid 13161529)
50. Li, Y., Aimone, J. B., Xu, X., Callaway, E. M. & Gage, F. H. Development of GABAergic inputs controls the contribution of maturing neurons to the adult hippocampal network. Proc. Natl Acad. Sci. USA 109, 4290-4295 (2012).
51. Ge, S., Sailor, K. A., Ming, G. L. & Song, H. Synaptic integration and plasticity of new neurons in the adult hippocampus. J. Physiol. 586, 3759-3765 (2008).
52. Martin, L. J. et al. Alpha5GABAA receptor activity sets the threshold for long-term potentiation and constrains hippocampus-dependent memory. J. Neurosci. 30, 5269-5282 (2010).
53. Clarkson, A. N., Huang, B. S., Macisaac, S. E., Mody, I. & Carmichael, S. T. Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. Nature 468, 305-309 (2010).
54. Wang, D. S. et al. Memory deficits induced by inflammation are regulated by alpha5-subunit-containing GABAA receptors. Cell Rep. 2, 488-496 (2012)
55. Atack, J. R. Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA. Pharmacol. Ther. 125, 11-26 (2010).
56. Escartin, C. & Bonvento, G. Targeted activation of astrocytes: a potential neuroprotective strategy. Mol. Neurobiol. 38, 231-241 (2008).
57. Barres, B. A. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 60, 430-440 (2008).
58. Mirra, S. S. et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486 (1991)
59. The National Institute on Aging and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol. Aging 18, S1-S2 (1997).
60. Montine, T. J. et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 123, 1-11 (2012).